Kornimate/medical-research-clean huggingface dataset:
fundus optical coherence tomography angiography evaluation for small-vessel health in cerebral small vessel disease

Conditions: Cerebral Small Vessel Diseases; Retinal Ischemia; Choroid; Injury

Summary: cerebral small-vessel disease (csvd) is a significant contributor to stroke and dementia, primarily impacting individuals over the age of 60. its prevalence exceeds 70% in the elderly population, imposing a substantial burden on brain health and the economy. optical coherence tomography angiography (octa) is a new type of optical diagnostic imaging technology for non-invasive detection, which can perform multi-dimensional quantitative assessment of fundus retinopathy. current studies have shown that fundus octa-derived parameters may have potential in characterizing imaging changes in csvd. however, the correlation between retinal/choroidal parameters on octa and the csvd imaging markers remains uncertain. fresh-csvd is a prospective, observational study that will use fundus octa-derived parameters to screen patients with csvd, explore the relationship between relevant parameters based on octa measurements and csvd, and evaluate the feasibility and clinical value of identification of csvd through fundus octa.


Eligibility criteria:
inclusion criteria: 1. older than 35 years old; 2. patients who underwent multimodal mri with any csvd imaging marker; 3. subjects who have signed informed consent. exclusion criteria: 1. patient who was unable to cooperate with examinations; 2. there are known diseases that may cause or worsen csvd (brain injury, down syndrome, alzheimer's disease, parkinson's disease, etc.); 3. there are known eye diseases or severe underlying fundus lesions that may impact fundus assessment; 4. suffering from serious systemic diseases, such as heart, liver, kidney diseases or major mental illnesses; 5. contraindications for imaging examinations exit criteria: 1. not meet the inclusion criteria. 2. for any poor adherence, not comply with the requirements of the follow-up, or safety reasons determined by investigator. 3. any adverse or serious adverse events during the study period judged by investigator
minimally invasive atlantoaxial lateral mass joint fusion (mis-palf) as a surgical treatment of atlantoaxial dislocation

Conditions: Atlantoaxial Dislocation

Summary: the conventional treatment for atlantoaxial dislocation is atlantoaxial fixation and fusion using the goel-harms technique, which involves a midline incision, dissection of the occipital muscle group, and is associated with disadvantages such as damage to the posterior ligament and muscle, high incidence of postoperative occipital cervical pain, and significant blood loss due to intraoperative bleeding and postoperative drainage. since 2013, various studies have reported minimally invasive posterior atlantoaxial lateral mass joint fusion techniques through muscle spaces, but previous studies were all case reports, without sufficient reliability and controlled studies. the department of orthopedics at peking university third hospital has been using the minimal invasive surgery-posterior atlantoaxial lateral mass joint fusion (mis-palf) technique for the treatment of atlantoaxial dislocation since 2015, with preliminary good clinical results. in order to further compare the advantages and disadvantages of the two surgical methods from a larger sample, a randomized controlled study is planned. the patients will be randomly divided into two groups, with the experimental group receiving the mis-palf surgery and the control group receiving open atlantoaxial fusion and fixation. there will be a 1-2 year follow-up to compare the safety and effectiveness of the two surgical methods for the treatment of atlantoaxial dislocation.


Eligibility criteria:
inclusion criteria: 1. age range from 0 to 80 years old, regardless of gender 2. diagnosed with atlantoaxial dislocation, suitable for posterior surgical treatment 3. index of assessment integrity 4. agree to participate in the study and sign the informed consent exclusion criteria: 1. atlantoaxial dislocation without surgical treatment 2. atlantoaxial dislocation treated by other operation, such as tarp

Keywords: atlantoaxial dislocation mis-palf minimal invasive surgery
physical activity and various aspects of quality of life in patients with pulmonary arterial hypertension (ph-pah)

Conditions: Pulmonary Arterial Hypertension; Physical Inactivity

Summary: evaluate whether education, a simple doctor's recommendation to increase physical activity in inactive patients, and self-monitoring of physical activity using a pedometer were effective and beneficial for patients with pulmonary arterial hypertension (pah)

each patient was educated about the benefits of pha in pah on the initial visit. patients wore pedometers (omron hj-321-e) for 2 weeks. after pha assessment, the patients were contacted by a physician. patients who walked \<5,000 steps per day were recommended to increase pha, and patients who walked ≥5,000 steps per day were recommended to maintain pha. patients wore pedometers for 3 months until their next visit. the primary endpoint was the number of steps after 12 weeks of the study; the secondary endpoint was the 6-minute walk test distance (6mwd), quality of life (sf-36), acceptance of the disease, and anxiety and depression level (hads).

Eligibility criteria:
inclusion criteria: * age equal to or greater than 18 years * pah diagnosis according to current guidelines, confirmed by right heart catheterization * optimal pharmacological treatment * stable clinical condition at least 3 months before inclusion in the study * informed consent to participate in your own exclusion criteria: * age under 18 years * a type of hypertension other than pah * a neurological or orthopedic disease that prevents walking and performing the 6-minute walk test * mental illness that prevents cooperation and assessment of quality of life survey * lack of consent to participate in the study

Keywords: pulmonary arterial hypertension education self-monitoring physical activity step count
combination of stereotactic radiosurgery and enhanced immunotherapy for recurrent glioblastomas(insituvac2)(csreig)

Conditions: Recurrent Glioblastoma

Summary: the study will investigate combined stereotactic radiosurgery and enhanced immunotherapy for recurrent glioblastomas. immune adjuvants will be injected intratumorally and systemically to induce antitumor-specific immunity after radiation induced immunological tumor cell death (icd). with radiation, tumor cells release tumor antigens that are captured by antigen presenting dendritic cells. immune adjuvants promote the presentation of tumor antigens and the priming of antitumor t lymphocytes. the combined treatment induces and amplifies the specific antitumor immunity in patients with recurrent glioblastomas, prolonging survivals of patients.

recurrent glioblatoma (rgbm) is an aggressive malignancy with a poor prognosis. there is no standard therapy and survival is less than 9 months. recently, personalized cancer immunotherapy has shown great promise in treating different types of cancers. however, effective immunotherapies for rgbms have yet to be established. the last clinical trial (insituvac1) showed promised results and this study was based on it. we will investigate whether combining stereotactic radiosurgery with intratumoral and systemic administration of enhanced immune adjuvants will improve the treatment outcome of rgbms. we will use several immune adjuvants that activate innate and adaptive immunity.

Eligibility criteria:
inclusion criteria: * 1. histopathologically confirmed rgbm * 2. age18-65 * 3. participants had undergone maximal surgical resection * 4. amount of dexamethasone was not more than 2mg/ days * 5. ability and willingness to sign informed consent * 6. karnofsky performance score of 70 or more * 7. normal liver and kidney function * 8. not accepted other treatment plan during the immunotherapy exclusion criteria: * 1. not conforming to the standard * 2. systemic illness or medical condition may pose additional risk,including cardiac, incompensated renal or liver function abnormalities;inflammatory and immune system diseases of rheumatic arthritis * 3. received other drugs for glioma therapy 60 days before participated * 4. allergy to immune adjuvant * 5. nervous system disease and diffuse leptomeningeal disease * 6. amount of dexamethasone was more than 2mg/days during the immunotherapy * 7. pregnant or lactation

Keywords: recurrent glioblastomas stereotactic radiosurgery enhanced immunotherapy
clinical study to evaluate the possible efficacy of metformin in patients with parkinson's disease

Conditions: Parkinson Disease

Summary: parkinson's disease (pd) is one of the most common neurodegenerative diseases characterized by the progressive loss of dopaminergic (da) neurons in the substantia nigra compacta (snc) and aggregation of lewy bodies in neurons. although aging, oxidative damage and neuroinflammation have been recognized to play crucial roles in the pathogenesis of pd, the precise etiology remains obscure. emerging evidence suggests pd is a systemic metabolic disease, and metabolic abnormality correlates with functional alternations in pd


Eligibility criteria:
inclusion criteria: age ≥ 18 years both males and females will be included negative pregnancy test and effective contraception. diagnosed parkinson's disease patient taking levodopa exclusion criteria: secondary causes of parkinsonism diabetic patients patients taking anti-inflammatory drugs atypical parkinsonian syndromes prior stereotaxic surgery for parkinson's disease pregnancy and lactation suffering from active malignancy addiction to alcohol and/or drugs known allergy to the studied medications
outcomes of disposable distal attachment device (endocuff and transparent plastic cap) assisted colonoscopy

Conditions: Colorectal Neoplasms

Summary: the purpose of the study is to compare the efficacy of device assisted colonoscopy (dac) with standard colonoscopy (sc) in detecting adenomas in a randomized fashion.


Eligibility criteria:
inclusion criteria: 1. patients undergoing first screening colonoscopy 2. patients undergoing subsequent surveillance colonoscopies with known history of prior colon polyps detected on prior screening colonoscopies. 3. ability to provide informed consent. exclusion criteria: 1. previous surgical resection of any part of the colon 2. history of colon cancer 3. history of inflammatory bowel disease 4. use of antiplatelet agents or anti-coagulants that precluded removal of polyps 5. poor general condition 6. history of polyposis syndrome or hereditary nonpolyposis colorectal cancer 7. inability to give informed consent.
empowering adolescents and young adults with sickle cell disease as partners in treatment decision making (empower-aya)

Conditions: Sickle Cell Disease

Summary: this study will evaluate the acceptability, feasibility, and preliminary efficacy of a shared decision making intervention for adolescents and young adults (ayas) with sickle cell disease (scd). 60 ayas with scd ages 15-25 and their caregivers and 8 scd providers will participate in the pilot pragmatic trial. ayas, caregivers, and providers will be recruited from nemours children's hospital, delaware (nch-de), nemours children's hospital in orlando, fl (nch-orl), and nemours children's health at wolfson children's hospital in jacksonville, fl (nch-jax). nch-de participants (n=30) will receive the sdm intervention including a virtual reality patient health education component, whereas nch-orl and nch-jax participants (n=30) will receive the sdm intervention with standard patient education materials (print, video). scd providers will be trained to use the toolkit components and will introduce decision aids during an outpatient clinic visit for ayas who are candidates for one or more disease-modifying therapies.


Eligibility criteria:
inclusion criteria: * patients diagnosed with scd ages 15-25 years receiving treatment at nemours and their caregivers will be included. patients must be deemed candidates for initiation of one or more disease-modifying therapies by their scd healthcare provider. * nemours scd healthcare providers will also be included. * english language fluency is a requirement for all participants. exclusion criteria: * patients/ caregivers who previously participated in usability testing of the intervention will be excluded. * patients will also be excluded if they have history of seizures, if their medical status or cognitive functioning preclude completion of interviews, or if no legal guardian is available to provide consent (for patients \< 18 years). * providers still completing training will be excluded.
association between the adenomyosis and the clinical outcomes of vaginal repair of cesareansectionscar defects

Conditions: Magnetic Resonance Imaging; Cesarean Section; Complications, Wound, Dehiscence

Summary: to examine the correlation between the occurrence of adenomyosis and the outcome of vaginal repair of cesarean section scar defects (csd), women with csd will be enrolled in this retrospective observational cohort study. according to preoperative magnetic resonance imaging (mri) findings, patients will be divided into two groups, the adenomyosis group and the non-adenomyosis group. they all will have vaginal excision and suture of csd and will be required to undergo examinations at 3- and 6-months after surgery. preoperative and postoperative clinical information will be collected.

women with csd will be enrolled in this study. according to preoperative magnetic resonance imaging (mri) findings, patients will be divided into two groups, the adenomyosis group and the non-adenomyosis group. they all underwent vaginal excision and suture of csd and will be required to undergo examinations at 3- and 6-months after surgery. preoperative and postoperative clinical information will be collected. optimal healing was defined as a duration of menstruation of no more than 7 days and a trm of no less than 5.30 mm after vaginal repair

Eligibility criteria:
inclusion criteria: * the inclusion criteria are non-pregnant patients who had one or more cesarean sections, patients who had intermenstrual spotting after the cesarean section or those in which the trm was less than 3.0 mm at the preoperative stage, and patients who underwent mri and tvs to evaluate the size of the defect and the trm before surgery exclusion criteria: * patients who had a history of chronic diseases (such as cerebro-cardiovascular diseases, malignancies and diabetes mellitus), endocrine disorders, menstrual irregularities before cesarean section, coagulation disorders, use of intrauterine devices, sub-mucous myoma, endometrial diseases, endometrial cysts, uterine fibroids, and adenomyosis after cesarean section

Keywords: magnetic resonance imaging cesarean scar defects vaginal repair
study to evaluate the use of rht-3201 in scorad reduction in young patients with atopic dermatitis

Conditions: Dermatitis, Atopic

Summary: the study's objective is to confirm that rht-3201 reduces the signs and symptoms of moderate atopic dermatitis determined by scorad, in patients aged 1 to 12 years, as compared to placebo. it will also be examined if the rht-3201 treatment, as compared to placebo, reduces the quantity of topical steroids used to treat disease flares


Eligibility criteria:
inclusion criteria: 1. patients and patients's parents or legal guardian have signed the informed consent. 2. aged 1 to 12 years, diagnosed with atopic dermatitis according to hanifin and rajka criteria 3. patients experienced ad symptoms for at least 6 months 4. scorad index of 20-40, both inclusive exclusion criteria: 1. patient has other active non-ad skin diseases that could difficult the atopic dermatitis evaluation 2. active cutaneous or extracutaneous infection (bacterial, viral, fungal) requiring systemic treatment within 2 weeks of baseline (localized molluscum contagiosum with \<20 lesions and viral warts are generally not reasons for exclusion.) 3. medical history of immunodeficiency syndrome, autoimmune disease or malignancy for systemic therapies that modulate the immune system 4. use of medications or treatments before baseline * treated with corticosteroids, immunosuppressive treatment within 4 weeks of baseline * treated with herbal medicines and health functional foods related to atopic dermatitis within 4 weeks of baseline * treated with phototherapy treatments to atopic dermatitis within 4 weeks of baseline * treated with probiotics within 4 weeks of baseline * treated with systemic antibiotics within 2 weeks of baseline * treated with topical steroids, topical immunomodulators, oral antihistamines, and topical antibiotic within 1 week of baseline (inhaled corticosteroids for asthma, no washout required if doses is stable) 5. medical history of infectious intestinal disease within 2 weeks before screening 6. history of hypersensitivity to components contained in study product (lactobacillus rhamnosus) 7. participation in any other investigational drug study in which receipt of an investigational study drug or health functional food within the past 4 weeks before screening (or, if known, administered within 5 times the half-life) 8. patients who are considered to be unacceptable in this study under the opinion of the investigator
treatment for depression in the primary care setting

Conditions: Depression

Summary: this study will compare a brief form of counseling to usual care for the treatment of minor depression in the primary care setting.

minor depression is one of the most common types of depressive disorders seen in primary care. the effectiveness and tolerability of antidepressants in patients with minor depression is unclear, and the development of alternative treatments is necessary. in the first phase of this study, participants are observed for 4 weeks to identify those most in need of depression-specific treatment. participants are then exposed to the problem-solving treatment for primary care (pst-pc), a six-session behavioral treatment for depression. after 4 weeks, patients who do not respond adequately to the treatment are randomly assigned to either continued pst-pc or to usual care for 9 weeks. participants are followed for 6 months after the study.

Eligibility criteria:
inclusion criteria: * primary care patient at dartmouth-hitchcock medical center (dhmc) * hamilton depression score \>= 10 and minor depression at time of entry and after 4 weeks of observation exclusion criteria: * psychosis, obsessive compulsive disorder (ocd), or post traumatic stress disorder (ptsd) * active substance abuse * receiving treatment for depression
women and children as the focus for control of schistosomiasis infections in the irrigations area of burkina faso

Conditions: Schistosomiasis

Summary: the purpose of this study is to examine the extent of schistosomasis infections in women and children, their daily activites that encumber contact with water and their knowledge and attitudes towards the prevention of schistosomiasis. the hypothesis that will be explored is that women and children spent more time with agricultural and household activities which bring them in contact with water and therefore give them an increased risk of being infected by schistosoma. prevention and control of schistosomiasis has to be focusing on women and children.

the study will be carried out in and irrigation area of burkina faso where people relay on water. the study applies several methodes; 1. parasitological survey: from thre villages 200 women and children are randomly sampled to have their urin and stool examined for parasittes. 2. observations: at each village sites at the irrigation canals where people meet and have their activities observations of the kind and the duration of watercontact will be observed. 3. focus group interview: in each village 5 focus group interviews will be conducted with 6 to 12 participants in each group 4. individual interviews: for the participant in the focus group interview a total of 45 participants will be selected for indept individual interviews 5. questionnaire: a total of 360 questionnairs will be distributed to participants in the parasitological survey, the focus group interviews and to participants who did not participate in any of the above mentioned. participants will be women and children from the three villages.

Eligibility criteria:
inclusion criteria: women and children from three villages

Keywords: schistosomiasis gender perspectives
intravenous ketorolac for postoperative pain in percutaneous nephrolithotomy

Conditions: Renal Calculus; Kidney Stones

Summary: the purpose of this study is to determine whether continuous intravenous ketorolac infusion reduces pain in patients who are having percutaneous nephrolithotomy for kidney stone disease.


Eligibility criteria:
inclusion criteria: * patients undergoing percutaneous nephrolithotomy for kidney stone disease exclusion criteria: * history of nonsteroidal antiinflammatory drug allergy * asthma * history of long-term opioid use * intraoperative blood loss greater than 300 ml * postoperative hemodynamic instability * active peptic ulcer disease * advanced renal impairment (creatinine \> 2.0 mg/dl) * bleeding diathesis * current use of probenecid * pregnancy

Keywords: percutaneous nephrolithotomy kidney stones
video education with result dependent disclosure

Conditions: Genetic Testing; Breast Cancer; Ovarian Cancer; Pancreatic Cancer; Prostate Cancer; Colorectal Cancer; Renal Cancer; Melanoma; Sarcoma

Summary: the overall study objective of this trial study is to identify and evaluate strategies to improve the accessibility of the video education with result dependent disclosure (verdi) model, increasingly utilized as a pre-genetic testing (pretest) education alternative in clinical practice, to better serve a more diverse patient population at risk for hereditary cancers.

this study consists of two parts: * qualitative assessment: * this part of the research study involves watching a brief educational video about genetic testing for inherited cancer risk (about 8 minutes) before completing a short interview by video or telephone with trained researchers. this interview will be digitally recorded for later review. participation in the study will be considered complete after the interview is finished. the qualitative assessment study will recruit 20 total participants. * the data gathered from this study will inform the refinement and adaptation of the verdi model for the subsequent randomized controlled trial. * randomized control trial: * a randomized controlled trial (rct) will evaluate the verdi model vs. standard genetic counseling in 1000 participants

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * current or prior diagnosis of breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, colorectal cancer, renal cancer, melanoma, or sarcoma * ability to understand spoken or written english or spanish in a healthcare context * ability to understand and the willingness to sign a written informed consent document * black or latinx (qualitative assessment study only) exclusion criteria: * prior cancer genetic testing * prior germline genetic testing * active hematologic malignancy (e.g. chronic lymphocytic leukemia) * currently pregnant * currently incarcerated

Keywords: genetic testing breast cancer ovarian cancer pancreatic cancer prostate cancer colorectal cancer renal cancer melanoma sarcoma